ABUS kills AB-506 HBV program due to new safety problem: https://www.globenewswire.com/news-release/2019/10/03/1925035/0/en/Arbutus-Announces-Decision-to-Discontinue-Development-of-AB-506-an-Oral-Capsid-Inhibitor-for-the-Treatment-of-Chronic-Hepatitis-B.html This is hardly a surprising development—see #msg-149943959. Bullish for ENTA.